Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc SRP-9001 BLA Update Call Transcript

Mar 16, 2023 / 08:30PM GMT
Release Date Price: $148.5 (+2.72%)
Operator

Good day, and thank you for standing by. Welcome to the Sarepta Therapeutics SRP-9001 BLA update conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Doug Ingram, President and Chief Executive Officer. Please go ahead, sir.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Thank you, Norma. Good evening, and thank you for joining our update call regarding the Biologics License Application, or BLA, for SRP-9001, our investigational gene therapy to treat Duchenne muscular dystrophy. As you will have seen in our accompanying release, we completed our late-cycle review this week and the FDA's Office of Therapeutic Products, or OTP, has now determined that they will hold an advisory committee, or Adcom, meeting for the SRP-9001 BLA.

As Duchenne muscular dystrophy is a devastating and life-ending disease and time is of the essence for the thousands of families living with Duchenne, the Center for Biologics

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot